HK1141983A1 - Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents - Google Patents

Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents

Info

Publication number
HK1141983A1
HK1141983A1 HK10108379.2A HK10108379A HK1141983A1 HK 1141983 A1 HK1141983 A1 HK 1141983A1 HK 10108379 A HK10108379 A HK 10108379A HK 1141983 A1 HK1141983 A1 HK 1141983A1
Authority
HK
Hong Kong
Prior art keywords
detecting
modulating
sensitivity
methods
tumour cells
Prior art date
Application number
HK10108379.2A
Other languages
English (en)
Inventor
Maria Kavallaris
Pei Pei Gan
Original Assignee
Newsouth Innovations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007901131A external-priority patent/AU2007901131A0/en
Application filed by Newsouth Innovations Pty Ltd filed Critical Newsouth Innovations Pty Ltd
Publication of HK1141983A1 publication Critical patent/HK1141983A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
HK10108379.2A 2007-03-05 2010-09-03 Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents HK1141983A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2007901131A AU2007901131A0 (en) 2007-03-05 Modulation of beta-tubulin expression in tumour cells
AU2007905307A AU2007905307A0 (en) 2007-09-28 Modulation of B-tubulin expression in tumour cells
PCT/AU2008/000298 WO2008106730A1 (en) 2007-03-05 2008-03-05 Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents

Publications (1)

Publication Number Publication Date
HK1141983A1 true HK1141983A1 (en) 2010-11-26

Family

ID=39737694

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10108379.2A HK1141983A1 (en) 2007-03-05 2010-09-03 Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents

Country Status (9)

Country Link
US (2) US20100159030A1 (xx)
EP (2) EP2644199B1 (xx)
JP (2) JP2010521657A (xx)
CN (2) CN103381269B (xx)
AU (1) AU2008222601B2 (xx)
CA (1) CA2679393A1 (xx)
HK (1) HK1141983A1 (xx)
IL (1) IL200767A (xx)
WO (1) WO2008106730A1 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012219611C1 (en) * 2011-02-24 2016-07-21 Basilea Pharmaceutica Ag Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles
CN106061981A (zh) * 2013-11-06 2016-10-26 索尔斯蒂斯生物有限公司 具有二硫化物基团的多核苷酸构建体
CA3001364A1 (en) * 2015-10-09 2017-04-13 Genzyme Corporation Improved flare (flow cytometry attenuated reporter expression) technology for rapid bulk sorting
CN110023321A (zh) 2016-08-17 2019-07-16 索尔斯蒂斯生物有限公司 多核苷酸构建体
SG11201903018WA (en) 2016-10-07 2019-05-30 Genzyme Corp Early post-transfection isolation of cells (epic) for biologics production
CN106435009B (zh) * 2016-12-27 2019-08-23 北京泱深生物信息技术有限公司 Tubb2a作为血液诊断标志物的用途
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825174B2 (en) 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
AU4413099A (en) * 1999-06-02 2000-12-28 Bristol-Myers Squibb Company Method and markers for prognosticating efficacy of anticancer agents
GB0415606D0 (en) * 2004-07-10 2004-08-18 Koninkl Philips Electronics Nv Lighting fixtures incorporating rf antennae
EP1828776A4 (en) * 2004-12-09 2010-03-17 Eisai R&D Man Co Ltd TUBULINISOTYPE SEARCH IN CANCER THERAPY WITH HEMIASTERLINANALOGES
WO2007057746A2 (en) * 2005-05-27 2007-05-24 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing chemotherapeutic drug resistance in a cancer cell

Also Published As

Publication number Publication date
IL200767A (en) 2015-09-24
EP2644199A1 (en) 2013-10-02
EP2136817A1 (en) 2009-12-30
US20100159030A1 (en) 2010-06-24
AU2008222601B2 (en) 2013-10-03
CN103381269B (zh) 2016-03-30
CA2679393A1 (en) 2008-09-12
EP2644199B1 (en) 2017-10-11
JP2010521657A (ja) 2010-06-24
IL200767A0 (en) 2010-05-17
EP2136817A4 (en) 2010-08-18
CN103381269A (zh) 2013-11-06
WO2008106730A1 (en) 2008-09-12
CN101778637A (zh) 2010-07-14
CN101778637B (zh) 2013-05-29
JP2013150603A (ja) 2013-08-08
AU2008222601A1 (en) 2008-09-12
US20160175339A1 (en) 2016-06-23
JP5766221B2 (ja) 2015-08-19

Similar Documents

Publication Publication Date Title
HK1141983A1 (en) Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents
BR112015010336A2 (pt) adesivos sensíveis à pressão incluindo grafite expansível
WO2013154826A3 (en) Methods for diagnosing impending diarrhea
BRPI0822998A2 (pt) Sistema de producao de material organico, utilizando material de biomassa e metodo
ZA201106848B (en) Method for the manufacture and creation of electrochromic thin film transistors with lateral or vertical structure using functionalized or non-functionalized vitroceramic,polymeric,metallic,or natural,synthetic or mixed cellulosic paper substrates
NO20073935L (no) Tetningsarrangement, samt tilhorende fremgangsmate
EP2518158A4 (en) PANCREATIC CANCER MARKERS, METHODS, KITS AND DETECTION BIOPUCES THEREFOR
WO2009158620A3 (en) Signatures and determinants associated with metastasis methods of use thereof
WO2010009337A3 (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
DK2438446T3 (da) Fremgangsmåder, reagenser og kits til flowcytometrisk immunfænotypebestemmelse
BRPI0812279A2 (pt) Métodos de detecção de adesivo.
EP2281903A4 (en) CANCER MARKER, METHOD FOR EVALUATING CANCER USING THE CANCER MARKER AND ASSESSING THE VALUE
WO2009149359A8 (en) Survival predictor for diffuse large b cell lymphoma
DE112008002883T8 (de) Kohlenstoffmaterial-Dosimeter
WO2013106844A3 (en) Methods and compositions for the treatment and diaginosis of pancreatic cancer
GB2496557A (en) Products and methods for identifying rock samples
ATE519805T1 (de) Zusetzung von russ zu einem polymerpulver
MX2009005278A (es) Productos de petroleo marcados y metodos para detectar los mismos.
GB2464417B (en) Security deterrent mark and methods of forming the same
NL1033720A1 (nl) Met afbuiging uitgerust CT-systeem met niet-rechthoekige detectorcellen.
CL2009001488A1 (es) Metodo para tratar una muestra liquida que contiene particulas microbiologicas.
HK1112928A1 (en) Cspcna isoform modifications and uses thereof
IN2012DN01379A (xx)
EP2157088A4 (en) FLUORESCENT INDOCYANINE DYES AND DERIVATIVES THEREOF FOR THE ANALYSIS OF BIOLOGICAL MACROMOLECULES
CL2009001907A1 (es) Metodo de deteccion precoz de cancer gastrico que comprende detectar la presencia de marcadores especificos de cancer gastrico en muestras de plasma.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180305